Kamada Ltd, Israel

Plasma protein fractions. Plasma protein fraction 200 g/l.
Plasma protein fraction  human albumin 200 g/l
VIAL Sol. for inf.  1 X50/100 ml  
Dose depends on ptt size, sev. of condit. and on contin. fluid or protein losses. See lit.
Restorat. and maint. of circul. blood vol. where vol. defic. has been demonstr. and use of a colloid is appropr. The choice of albumin rather than artif. colloid will dep. on the clin. situat. of the indiv. ptt, based on official recomm.
C/I: Hypersens.

Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg / 1 ml.
Concentr. for sol. for IV vials:1 X 4 ml/16ml
Dosage to be adj. indiv. as per med. condit. and combinat. regimen accord. to prescrib. info.
In combin. with fluoropyrimidine-based chemother.  for metast. carcin. of the colon or rectum.- In addit. to platinum - based chemoth. for first - line tmt. of unresectable adv. metast. or recurr. non- small cell lung cancer other than predom. squam. cell histol. –In combin. with interferon alfa-2a for first line of adv. and /or metast. renal cell cancer. In combin. with paclitaxel for first-line tmt. of metast. breast cancer.- As a sgle. agent, for glioblastoma in pts. with progress. dis. following prior ther.- In combin. with carboplatin and paclitaxel, for front-line tmt. of adv.(FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or prim. peritoneal cancer at high risk for recurr.- In combin. with carboplatin and gemcitabine, for first recurr. of platinum-sensit. epithelial ovarian, fallopian tube or prim. peritoneal cancer pts. who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.- In combin. with topotecan, or pegylated liposomal doxorubicin for platinum-resistant recurr. epithelial ovarian, fallopian tube, or prim. peritoneal cancer pts. who received no more than 2 prior chemother. regimens and who have not receved prior ther. with bevacizumab or other VEGF inhib. or VEGF recept.–targeted agents –In combin. with paclitaxel and cisplatin or paclitaxel and topotecan for persistent, recurr., or metast. carcin. of the cervix.- In combin. with erlotinib, for first-line tmt. of unresectable adv., metast. or recurr. non-squam. non-small cell lung cancer with Epid. Growth Factor Recept.(EGFR) activat. mutat.
C/I: hypersens, incl. to Chin. Hamster Ovary (CHO) cell prod. or other recomb. human or humanized antibodies. Pregn.

Corticosteroid, β2 Agonist. Beclometasone Dipropionate 100 mcg/metered dose, 200 mcg/metered dose, Formoterol Fumarate (dihydrate) 6 mcg/metered dose.
INHALER.(pressurised  sol. for inhal.):1×120 actuat.
Asthma: Maint. therapy for pts. 18 yrs. and above- 1, 2 inhal. ×2/d. max. dly. dose is 4 inhal. Maint. & reliever ther.: Pts. 18 yrs. and above- 1 inhal. ×2/d. max. dly. dose is 8 inhal.COPD: For pts. 18 yrs. and above- 2 inhal. ×2/d. See lit.
Asthma: Regular tmt. of asthma where use of a combin. product (inhaled corticost.&long-acting β2-agonist) is approp. Pts. not adequate. control. with inhal. corticoster. and ‘as needed’ inhal. rapid-act. beta2-agonist. Pts. already adequat. control. on both inhal. corticoster. and long-act. β2-agonist. COPD :Symptom. tmt. of pts. with severe COPD (FEV1 < 50% predicted normal) and a hist. of repeated exacerb., who have signific. sympt. despite regular ther. with long-act. bronchodilators.
C/I: Hypersens.

Corticosteroid/Beta 2-Agonist. Beclometasone Dipropionate 200mcg/metered dose, Formoterol Fumarate 6mcg/metered dose.
INHALER. (Pressurised sol. for inhal).:1×120 actuation.
Adults 18 yrs. and above:
Two inhalations twice dly.
The max. dly. dose is 4 inhalat.
Foster 200/6 should be used as mainten. therapy only. A lower strength (Foster 100/6) is available for mainten. and reliever ther.
Indicated in the regular tmt. of asthma in adult. where use of a comb. product (inhaled corticosteroid and long-act. Β₂-ag.) is appropriate:
Pts. not adequate. control. with inhaled corticosteroids and 'as needed' inhaled rapid-acting Β2-agonist.
Pts. already adequat. controlled on both inhaled corticosteroids and long-act. Β2-ag. C/I: Hypersens.

Alpha 1-antitrypsin (AAT) 1 g / 50 ml.
VIAL (sol. for infus.): 1 x 50 ml. I.V. use
only. 60 mg/kg bdy. wt. 1 x wkly.
See lit.
Chron. augmentat./maint. ther. congen.
defic. alpha1-proteinase inhib. (Alpha1-
PI), also known as alpha1-antitrypsin
(AAT) defic. and clin. evidence
emphysema.
C/I: Immunoglobulin A (IgA) defic. with
antibodies against IgA. Hypersens., incl.
anaphylax. to Alpha1-PI product.

Blood Coagulant. Human Coagulation Factor VIII 250, 500, 1000 IU / vial.
PWDR (I.V. INJECT.): 1+ solvent. See lit.
Tmt. and proph. bleed. in hemophil. A
(congen. factor VIII defic.) with acq. factor
VIII defic.